Tyrrell C J
Research Unit, Plymouth General Hospital, United Kingdom.
Prostate Suppl. 1992;4:97-104. doi: 10.1002/pros.2990210515.
Casodex, a pure potent non-steroidal anti-androgen, has been shown in a phase II clinical trial program to be very well tolerated and to have fewer side-effects compared with other anti-androgens. The most commonly reported side-effects (prompted by direct questioning) were breast tenderness (63.4%), breast swelling (52.5%), and hot flashes (23.6%). Gastrointestinal disturbances, hepatic impairment, alcohol intolerance, and problems with light adaptation are not associated with Casodex treatment. In this study, Casodex (50 mg once daily) was evaluated in 267 patients, 130 of whom have received it for more than 1 year. On assessment of best objective response, 55.5% of patients showed partial regression, 15.6% stable disease, 17.1% progression, and 11.8% were not assessable. These results are comparable with other standard hormonal therapies for advanced prostate cancer.
康士得（Casodex）是一种纯的强效非甾体类抗雄激素药物，在一项II期临床试验项目中已表明，与其他抗雄激素药物相比，它耐受性良好且副作用较少。最常报告的副作用（通过直接询问得出）为乳房压痛（63.4%）、乳房肿胀（52.5%）和潮热（23.6%）。胃肠道紊乱、肝功能损害、酒精不耐受以及光适应问题与康士得治疗无关。在本研究中，对267例患者评估了康士得（每日一次，每次50毫克），其中130例患者接受该药物治疗超过1年。在评估最佳客观反应时，55.5%的患者显示部分消退，15.6%疾病稳定，17.1%进展，11.8%无法评估。这些结果与晚期前列腺癌的其他标准激素疗法相当。
